This content is from: Premium
Valeant Debacle is Bad News for Ackman, Ubben, Others
The healthcare stock fell so far on Wednesday that trading was briefly halted. But some hedge fund die-hards say the bloodbath is a buying opportunity.
Michael Pearson, Valeant Pharmaceuticals International (Bloomberg) This Valeant Pharmaceuticals International sell-off is starting to get ugly. Shares of the fast-growing, acquisitive drug peddler plummeted another 19 percent Wednesday — after briefly falling as much as 40 percent during the day — following the publication of a short-selling specialist’s scathing report on the
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.